ProKidney
PROK
80 hedge funds and large institutions have $232M invested in ProKidney in 2022 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 22 increasing their positions, 11 reducing their positions, and 24 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 11
2.04% more ownership
Funds ownership: 89.42% → 91.45% (+2%)
4% more capital invested
Capital invested by funds: $223M → $232M (+$9.22M)
11% less funds holding
Funds holding: 90 → 80 (-10)
42% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 24
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$10.1M |
| 2 |
ACA
Arena Capital Advisors
Los Angeles,
California
|
+$7.27M |
| 3 |
6CM
683 Capital Management
New York
|
+$4.93M |
| 4 |
HSBC Holdings
London,
United Kingdom
|
+$4.39M |
| 5 |
Millennium Management
New York
|
+$4.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PWAM
Park West Asset Management
San Francisco,
California
|
-$10.9M |
| 2 |
FC
Finepoint Capital
Boston,
Massachusetts
|
-$9.7M |
| 3 |
RIA
RP Investment Advisors
Toronto,
Ontario, Canada
|
-$5.33M |
| 4 |
LCM
LH Capital Markets
New York
|
-$4.95M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.96M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
101
Morgan Stanley
New York
| – | -$94K | -9,456 | Closed |
|
102
UBS Group
Zurich,
Switzerland
| – | -$7K | -755 | Closed |
|
|
TRCT
103
Tower Research Capital (TRC)
New York
| – | -$5K | -536 | Closed |
|
|
WCMNY
104
Westchester Capital Management (New York)
Valhalla,
New York
| – | +$266 | +27 | New |
|
PROK Hedge Fund Activity: Q1 2022 in Review
80 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in ProKidney (PROK) for Q1 2022, worth a combined $232M — up 4.1% from $223M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of PROK and 14 opened new positions — a net loss of 10 holders — while 11 trimmed existing stakes and 22 added.
The largest buyer was Citadel Advisors, adding an estimated $10.1M. The largest seller was Park West Asset Management, exiting entirely with an estimated $10.9M sold.
- 80 institutional investors held ProKidney (PROK) as of Q1 2022, down from 90 in Q4 2021.
- Funds reported $232M of ProKidney stock for Q1 2022, up 4.1% quarter-over-quarter.
- 14 funds opened new ProKidney positions in Q1 2022 and 24 closed out, a net change of -10 holders.
- The largest ProKidney buyer in Q1 2022 was Citadel Advisors, an estimated $10.1M added.
- The largest ProKidney seller in Q1 2022 was Park West Asset Management, an estimated $10.9M sold.
Based on aggregated 13F filings for Q1 2022.